MX2021000926A - Agentes de obtencion de imagenes para el radiomarcado de albuminas exogenas y endogenas. - Google Patents
Agentes de obtencion de imagenes para el radiomarcado de albuminas exogenas y endogenas.Info
- Publication number
- MX2021000926A MX2021000926A MX2021000926A MX2021000926A MX2021000926A MX 2021000926 A MX2021000926 A MX 2021000926A MX 2021000926 A MX2021000926 A MX 2021000926A MX 2021000926 A MX2021000926 A MX 2021000926A MX 2021000926 A MX2021000926 A MX 2021000926A
- Authority
- MX
- Mexico
- Prior art keywords
- radiolabeling
- exogenous
- imaging agents
- endogenous albumin
- albumin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702081P | 2018-07-23 | 2018-07-23 | |
| PCT/US2019/042025 WO2020023247A1 (en) | 2018-07-23 | 2019-07-16 | Imaging agents for radiolabeling exogenous and endogenous albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000926A true MX2021000926A (es) | 2021-03-31 |
Family
ID=69181921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000926A MX2021000926A (es) | 2018-07-23 | 2019-07-16 | Agentes de obtencion de imagenes para el radiomarcado de albuminas exogenas y endogenas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210353783A1 (https=) |
| EP (1) | EP3826685A4 (https=) |
| JP (1) | JP7395194B2 (https=) |
| KR (1) | KR20210035213A (https=) |
| CN (1) | CN112823028A (https=) |
| AU (1) | AU2019309242B2 (https=) |
| BR (1) | BR112021001314A2 (https=) |
| CA (1) | CA3107328A1 (https=) |
| IL (1) | IL280308B2 (https=) |
| MX (1) | MX2021000926A (https=) |
| WO (1) | WO2020023247A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3263646A1 (en) * | 2022-07-29 | 2024-07-18 | Curium Us Llc | [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof |
| AU2024317528A1 (en) | 2023-07-31 | 2026-03-05 | Curium Us Llc | [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5094950A (en) * | 1988-06-07 | 1992-03-10 | Nihon Medi-Physics Co., Ltd. | Diethylenetriamine pentaacetic acid derivatives |
| US20050233307A1 (en) * | 2002-09-12 | 2005-10-20 | Kyle Gee | Site-specific labeling of affinity tags in fusion proteins |
| US20040208828A1 (en) * | 2003-02-04 | 2004-10-21 | Lutz Lehmann | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents |
| DE10305463A1 (de) * | 2003-02-04 | 2004-08-12 | Schering Ag | Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel |
| KR100695744B1 (ko) * | 2005-05-03 | 2007-03-19 | 한국원자력연구소 | 디티피에이(ｄｔｐａ) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제 |
| WO2008070384A2 (en) * | 2006-11-06 | 2008-06-12 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of preparing macromolecular contrast agents and uses thereof |
| FR2909881A1 (fr) * | 2006-12-14 | 2008-06-20 | Inst Nat Sante Rech Med | Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation |
| EP2630971B8 (en) * | 2012-02-21 | 2017-12-13 | Vergell Medical S.A. | Combinations of albumin-based drug delivery systems |
-
2019
- 2019-07-16 KR KR1020217004394A patent/KR20210035213A/ko not_active Ceased
- 2019-07-16 CA CA3107328A patent/CA3107328A1/en active Pending
- 2019-07-16 IL IL280308A patent/IL280308B2/en unknown
- 2019-07-16 BR BR112021001314-8A patent/BR112021001314A2/pt unknown
- 2019-07-16 AU AU2019309242A patent/AU2019309242B2/en not_active Expired - Fee Related
- 2019-07-16 EP EP19841111.8A patent/EP3826685A4/en not_active Withdrawn
- 2019-07-16 JP JP2021503750A patent/JP7395194B2/ja active Active
- 2019-07-16 US US17/262,133 patent/US20210353783A1/en active Pending
- 2019-07-16 MX MX2021000926A patent/MX2021000926A/es unknown
- 2019-07-16 CN CN201980048717.4A patent/CN112823028A/zh active Pending
- 2019-07-16 WO PCT/US2019/042025 patent/WO2020023247A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3826685A4 (en) | 2022-04-06 |
| JP2021532123A (ja) | 2021-11-25 |
| JP7395194B2 (ja) | 2023-12-11 |
| EP3826685A1 (en) | 2021-06-02 |
| WO2020023247A1 (en) | 2020-01-30 |
| IL280308B2 (en) | 2024-09-01 |
| KR20210035213A (ko) | 2021-03-31 |
| CN112823028A (zh) | 2021-05-18 |
| AU2019309242A1 (en) | 2021-03-11 |
| BR112021001314A2 (pt) | 2021-05-11 |
| US20210353783A1 (en) | 2021-11-18 |
| CA3107328A1 (en) | 2020-01-30 |
| IL280308A (en) | 2021-03-01 |
| AU2019309242B2 (en) | 2025-05-29 |
| IL280308B1 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002401A (es) | Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos. | |
| MY202410A (en) | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
| MX2019008413A (es) | Celulas pluripotentes inmunodiseñadas. | |
| EP4582144A3 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| SG11201808607SA (en) | Medicine obtained by combining fxr agonist and arb | |
| FR3021970B1 (fr) | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs | |
| UY35961A (es) | Anticuerpos y fragmentos anti-vista | |
| MX2023012451A (es) | Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer. | |
| WO2018022881A3 (en) | Methods for identifying lilrb-blocking antibodies | |
| MX2019001572A (es) | Método de cromatografía para cuantificar un tensioactivo no iónico en una composición que comprende el tensioactivo no iónico y un polipéptido. | |
| PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
| MX389899B (es) | Compuesto macrocíclico y sus usos. | |
| MA48939A (fr) | Compositions comprenant des souches bactériennes | |
| WO2017142895A8 (en) | Compositions and methods for treating clostridium associated diseases | |
| WO2019157527A3 (en) | Methods related to parkinson's disease and synucleinopathies | |
| MX2019003994A (es) | Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial. | |
| EP4512830A3 (en) | Antibodies useful in cancer diagnosis | |
| MX2021000926A (es) | Agentes de obtencion de imagenes para el radiomarcado de albuminas exogenas y endogenas. | |
| PH12020551912A1 (en) | Use for preventing and treating myeloid-derived suppressor cell-related diseases | |
| TWD200994S (zh) | 腕帶之部分 | |
| MX2020008408A (es) | Imagenologia y terapia dirigidas por la granzima b. | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |